top of page

DISEASE EXPERTISE

Model Stewardship brings deep technical knowledge across infectious disease modeling, clinical research design, and evidence synthesis for global health impact.

PAST PROJECTS

My work has directly supported:

  • M72 TB vaccine phase 3 trial design (with Gates Medical Research Institute)

  • Nutrition-TB intervention clinical trial (with Wellcome Trust, Novo Nordisk Foundation)

  • COVID-19 vaccine prioritization strategies (with CEPI)

  • TB program optimization with South African, Pakistani, and Nigerian ministries of health

  • TB hotspot prediction (award-winning model in 2019 TB Hackathon sponsored by Stop TB Partnership)​

TB Hackathon Ceremony - 2019

TUBERCULOSIS

Over a decade modeling TB transmission, intervention impact, and program optimization. Developed agent-based models for India, South Africa, Nigeria, and other high-burden settings.

Nigeria TB hotspot map

RESPIRATORY PATHOGENS

Research background in H5N1, SARS-CoV, and other highly pathogenic respiratory viruses. Meta-analysis of immune responses to emerging infectious diseases, and translational research to new diagnostics.

High-pathogenicity gene signature

COVID-19 & PANDEMIC PREPAREDNESS

Supported COVID-19 vaccine rollout strategies with CEPI. Experience in rapid epidemic modeling and pandemic preparedness planning.

COVID modeling with CEPI

SELECTED PUBLICATIONS

  • Selvaraj P, Wagner BG, Chao DL, Jackson ML, Breugelmans JG, Jackson N, Chang ST. Rural prioritization may increase the impact of COVID-19 vaccines in a representative COVAX AMC country. PLOS Glob Public Health. 2022;2(1):e0000053. [Link]

  • Alba S, Rood E, Mecatti F, Ross JM, Dodd PJ, Chang ST, et al. TB Hackathon: Development and comparison of five models to predict subnational TB prevalence in Pakistan. Trop Med Infect Dis. 2022;7(1):13. [Link]

  • Chang ST, Chihota VN, Fielding KL, Grant AD, Houben RM, White RG, Churchyard GJ, Eckhoff PA, Wagner BG. Small contribution of gold mines to the TB epidemic in South Africa: a modeling study. BMC Med. 2018;16(1):52. [Link]

  • Menzies NA, Gomez GB, Bozzani F, Chatterjee S, Foster N, Baena IG, Chang ST, et al. Cost-effectiveness of aggressive TB action in China, India, and South Africa: combined analysis of nine models. Lancet Glob Health. 2016;4(11):e816–e826. [Link]

  • Houben RMGJ, Menzies NA, Sumner T, Huynh GH, Arinaminpathy N, Goldhaber-Fiebert JD, Chang ST, et al. Feasibility of achieving 2025 WHO TB targets in South Africa, China, and India: analysis of 11 models. Lancet Glob Health. 2016;4(11):e806–e815. [Link]

  • Chang ST, Thomas MJ, Sova P, Green RR, Palermo RE, Katze MG. Next-generation sequencing of small RNAs from HIV-infected cells reveals novel microRNAs. mBio. 2013;4(1):e00549-12. [Link]

  • Chang ST, Tchitchek N, Ghosh D, Benecke A, Katze MG. A chemokine gene expression signature predicts pathogenicity of viral respiratory infections. BMC Syst Biol. 2011;5:202. [Link]

  • Chang ST, Linderman JJ, Kirschner DE. Multiple mechanisms allow M. tuberculosis to inhibit MHC class II antigen presentation by macrophages. Proc Natl Acad Sci USA. 2005;102(12):4530–4535. [Link]

bottom of page